Medtronic has reported late-breaking data from the randomised Evolut Low Risk Trial’s five-year outcomes of the Evolut ...

Aortic valve stenosis' is an often-overlooked condition and a growing health concern in ageing societies such as Thailand. With an increasing elderly population and a rise in age-related valve ...

Patients with aortic stenosis were excluded from earlier trials of the SGLT2 inhibitor, but new data confirm they too can ...

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had ...

A new method of alerting clinical care providers holds promise for increasing treatment and improving survival for patients with severe aortic ...

Here are the biggest stories out of ACC 2025: Five-year data from the Medtronic Evolut Low Risk Trial confirmed that its ...

Patients with severe aortic stenosis at low surgical risk who underwent supra-annular, self-expanding Evolut transcatheter ...

With the aging of the population, aortic stenosis affects a growing number of patients, with a prevalence of 12.4% among persons who are at least 75 years of age, among whom 3.4% have severe ...

BayCare's Morton Plant Hospital in Clearwater recently completed the world's first TAV-in-TAV as part of a study called ...

Olive Hospital has achieved a major breakthrough in the field of Interventional Cardiology by successfully completing its ...

CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at ...

Patients with symptomatic severe aortic stenosis undergoing CoreValve or Evolut TAVI have better 5-year bioprosthetic valve ...